Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2025Frontiers in ImmunologyOpen Access

Immunotherapy combined with definitive chemoradiotherapy for locally advanced unresectable esophageal squamous cell carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

YHYong Sang HongQTQiang‐Wu TanYLYixin Li

Discussion

Loading...

Member takes

Overview

Observational study assesses overall survival and safety in patients with unresectable esophageal cancer, indicating immunotherapy may enhance treatment outcomes.

Key Points

  • ICIs combined with dCRT resulted in a 2-year overall survival rate of 64.3% among 165 patients with LA-ESCC.
  • The study found a 2-year progression-free survival rate of 50.2% after following patients for a median of 24 months.
  • Induction therapy before dCRT did not show improvement in overall or progression-free survival metrics.
  • The most common adverse event observed was grade 3 or worse lymphopenia, impacting 60.0% of patients.

Cite This Study

Hong et al. (2025) studied this question.

synapsesocial.com/papers/68dd89d7fe798ba2fc497a10https://doi.org/10.3389/fimmu.2025.1646568
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1192. INDUCTION IMMUNOCHEMOTHERAPY FOLLOWED BY CONCURRENT CHEMORADIOTHERAPY FOR UNRESECTABLE LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (RICE): PRELIMINARY RESULTS2025
  2. 2Efficacy and safety of concurrent chemoradiotherapy combined with immunotherapy for locally advanced esophageal squamous cell carcinoma: a retrospective cohort study2026
  3. 3Comparing the Efficacy and Safety of IC-ICCRT-IO With CT-CCRT for Unresectable Locally Advanced ESCC: A Retrospective Analysis2025
  4. 4207. LOW-DOSE INVOLVED-FIELD RT, PLUS IMMUNOCHEMOTHERAPY SHOWED EXCELLENT EFFICACY AND LOW TOXICITIES IN UNRESECTABLE LA-ESCC: A PROSPECTIVE PHASE II STUDY2025
  5. 5Real-world study of first-line immunotherapy combined with chemoradiotherapy in esophageal squamous cell carcinoma2025 · 2 citations